Sunita R Setlur
Overview
Explore the profile of Sunita R Setlur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Oldridge D, Banerjee S, Setlur S, Sboner A, Demichelis F
Nucleic Acids Res
. 2010 Feb;
38(10):3275-86.
PMID: 20156996
The detection of copy number variants (CNV) by array-based platforms provides valuable insight into understanding human diversity. However, suboptimal study design and data processing negatively affect CNV assessment. We quantitatively...
12.
Setlur S, Chen C, Hossain R, Ha J, Van Doren V, Stenzel B, et al.
Cancer Epidemiol Biomarkers Prev
. 2010 Jan;
19(1):229-39.
PMID: 20056642
Purpose: Dihydrotestosterone (DHT) is an important factor in prostate cancer (PCA) genesis and disease progression. Given PCA's strong genetic component, we evaluated the possibility that variation in genes involved in...
13.
14.
Rickman D, Pflueger D, Moss B, VanDoren V, Chen C, De La Taille A, et al.
Cancer Res
. 2009 Mar;
69(7):2734-8.
PMID: 19293179
Chromosomal rearrangements account for all erythroblast transformation-specific (ETS) family member gene fusions that have been reported in prostate cancer and have clinical, diagnostic, and prognostic implications. Androgen-regulated genes account for...
15.
Demichelis F, Setlur S, Beroukhim R, Perner S, Korbel J, LaFargue C, et al.
Genes Chromosomes Cancer
. 2009 Jan;
48(4):366-80.
PMID: 19156837
Emerging molecular and clinical data suggest that ETS fusion prostate cancer represents a distinct molecular subclass, driven most commonly by a hormonally regulated promoter and characterized by an aggressive natural...
16.
Setlur S, Mertz K, Hoshida Y, Demichelis F, Lupien M, Perner S, et al.
J Natl Cancer Inst
. 2008 May;
100(11):815-25.
PMID: 18505969
Background: The majority of prostate cancers harbor gene fusions of the 5'-untranslated region of the androgen-regulated transmembrane protease serine 2 (TMPRSS2) promoter with erythroblast transformation-specific transcription factor family members. The...
17.
Kelly K, Setlur S, Ross R, Anbazhagan R, Waterman P, Rubin M, et al.
Cancer Res
. 2008 Apr;
68(7):2286-91.
PMID: 18381435
Early detection and diagnosis of prostate cancer is key to designing effective treatment strategies. Microarrays have resulted in the discovery of hepsin (HPN) as a biomarker for detection of prostate...
18.
Setlur S, Royce T, Sboner A, Mosquera J, Demichelis F, Hofer M, et al.
Cancer Res
. 2007 Nov;
67(21):10296-303.
PMID: 17974971
Microarrays have been used to identify genes involved in cancer progression. We have now developed an algorithm that identifies dysregulated pathways from multiple expression array data sets without a priori...
19.
Mertz K, Setlur S, Dhanasekaran S, Demichelis F, Perner S, Tomlins S, et al.
Neoplasia
. 2007 Apr;
9(3):200-6.
PMID: 17401460
Recent studies have established that a significant fraction of prostate cancers harbor a signature gene fusion between the 5' region of androgen-regulated TMPRSS2 and an ETS family transcription factor, most...
20.
Setlur S, Dighe R
Glycoconj J
. 2006 Dec;
24(1):97-106.
PMID: 17143726
The strategy of translationally fusing the subunits of heterodimeric proteins into single chain molecules is often used to overcome the mutagenesis-induced defects in subunit interactions. The approach of fusing the...